ANCA associated vasculitis: The journey to complement-targeted therapies

Area of Science:

• Immunology
• Nephrology
• Rheumatology

Background:

• ANCA-associated vasculitis (AAV) is a severe, relapsing condition with high mortality, often due to infections and organ damage.
• Current treatments (glucocorticoids, cyclophosphamide, rituximab) are insufficient, leading to a nine-fold increased mortality risk in the first year.
• Emerging evidence highlights the significant role of complement system activation, especially the alternative pathway, in AAV pathogenesis.

Purpose of the Study:

• To review the clinical evidence supporting the role of complement activation in ANCA-associated vasculitis.
• To discuss potential therapeutic strategies targeting complement components for AAV treatment.

Main Methods:

• Review of current clinical evidence on complement activation in AAV.
• Discussion of therapeutic strategies targeting complement pathways.

Main Results:

• Complement system activation, particularly the alternative pathway, is implicated in AAV pathogenesis.
• Detection of complement components in circulation and urine correlates with disease activity.
• Complement components like C5a represent potential therapeutic targets.

Conclusions:

• Targeting the complement system offers a promising avenue for novel AAV therapies.
• Personalized treatment strategies based on complement activation markers may improve patient outcomes.
• Complement-targeted therapy holds potential for near-future clinical application in AAV.